114 related articles for article (PubMed ID: 3190793)
21. In vitro and in vivo augmentation by muroctasin of the production of the third component of complement by murine macrophages.
Endo N
Arzneimittelforschung; 1988 Jul; 38(7A):993-6. PubMed ID: 3190805
[TBL] [Abstract][Full Text] [Related]
22. Restorative activity of muroctasin on leukopenia associated with anticancer treatment.
Tsubura E; Nomura T; Niitani H; Osamura S; Okawa T; Tanaka M; Ota K; Nishikawa H; Masaoka T; Fukuoka M
Arzneimittelforschung; 1988 Jul; 38(7A):1070-4. PubMed ID: 3190800
[TBL] [Abstract][Full Text] [Related]
23. Reproductive toxicity of muroctasin.
Akiyama Y; Mochida K; Yamashita N; Takayama S
Arzneimittelforschung; 1988 Jul; 38(7A):1040-2. PubMed ID: 3190799
[TBL] [Abstract][Full Text] [Related]
24. Induction of colony-stimulating factor and stimulation of stem cell proliferation by injection of muroctasin.
Yamaguchi F; Akasaki M; Tsukada W
Arzneimittelforschung; 1988 Jul; 38(7A):980-3. PubMed ID: 3263869
[TBL] [Abstract][Full Text] [Related]
25. Acute toxicity of muroctasin in mice, rats and dogs.
Ono Y; Iwasaki T; Furuhama K; Onodera T
Arzneimittelforschung; 1988 Jul; 38(7A):1022-4. PubMed ID: 3190794
[TBL] [Abstract][Full Text] [Related]
26. [Muroctasin, a muramyl dipeptide derivative].
Sosnowska D; Dzierzbicka K; Myśliwski A; Kołodziejczyk AM
Postepy Hig Med Dosw; 1992; 46(5):521-30. PubMed ID: 1298958
[TBL] [Abstract][Full Text] [Related]
27. Enhancement of serum antibody production in mice by oral administration of lipophilic derivatives of muramylpeptides and bacterial lipopolysaccharides with bovine serum albumin.
Ogawa T; Kotani S; Shimauchi H
Methods Find Exp Clin Pharmacol; 1986 Jan; 8(1):19-26. PubMed ID: 3702542
[TBL] [Abstract][Full Text] [Related]
28. Augmentation by priming with interferon-gamma of the binding of a muramyl dipeptide derivative to macrophages resulting in synergistic macrophage activation.
Nagao S; Sato K; Osada Y
Jpn J Cancer Res; 1987 Jan; 78(1):80-6. PubMed ID: 3102442
[TBL] [Abstract][Full Text] [Related]
29. Elevation by muroctasin of the serum level of the complement subcomponent C1q in mice and of its biosynthesis by cultured mouse peritoneal macrophages.
Endo N; Okuda T; Osada Y; Zen-yoji H
Arzneimittelforschung; 1990 Jan; 40(1):58-61. PubMed ID: 2340001
[TBL] [Abstract][Full Text] [Related]
30. Enhancement of serum antibody production in mice by oral administration of lipophilic derivatives of muramyl peptides and bacterial lipopolysaccharides with bovine serum albumin.
Ogawa T; Kotani S; Shimauchi H
Methods Find Exp Clin Pharmacol; 1986 Feb; 8(2):117-25. PubMed ID: 3713372
[TBL] [Abstract][Full Text] [Related]
31. Stimulation of macrophages by muroctasin to produce colony-stimulating factors.
Akahane K; Yamaguchi F; Kita Y; Une T; Osada Y
Arzneimittelforschung; 1990 Feb; 40(2 Pt 1):179-83. PubMed ID: 1692219
[TBL] [Abstract][Full Text] [Related]
32. Protective effect of MDP-Lys(L18), a synthetic derivative of muramyldipeptide, on murine cytomegalovirus infection.
Eizuru Y; Nakagawa N; Hamasuna R; Minamishima Y
Nat Immun; 1992; 11(4):225-36. PubMed ID: 1384831
[TBL] [Abstract][Full Text] [Related]
33. Muroctasin. A new muramyl dipeptide derivative, MDP-Lys(L18).
Arzneimittelforschung; 1988 Jul; 38(7A):951-1074. PubMed ID: 3190801
[No Abstract] [Full Text] [Related]
34. Augmentation of immune responses by a muramyl dipeptide analog, MDP-Lys(L18).
Akasaki M; Takashi T; Kita Y; Tsukada W
Agents Actions; 1987 Oct; 22(1-2):144-50. PubMed ID: 3318323
[TBL] [Abstract][Full Text] [Related]
35. Effect of muramyl dipeptide and its stearoyl derivatives on resistance to Sendai virus infection in mice.
Ishihara C; Hamada N; Yamamoto K; Iida J; Azuma I; Yamamura Y
Vaccine; 1985 Dec; 3(5):370-4. PubMed ID: 2417426
[TBL] [Abstract][Full Text] [Related]
36. Restorative effect of muroctasin on leukopenia caused by anticancer chemotherapy in lung cancer. Comparative study by envelope method.
Fukuoka M; Takada M; Takifuji N; Sakai N; Ryu S; Masuda N; Matsui K; Negoro S; Kusunoki Y; Tubura E
Arzneimittelforschung; 1989 Jan; 39(1):90-3. PubMed ID: 2719748
[TBL] [Abstract][Full Text] [Related]
37. Production of interleukin-6 from macrophages by MDP-Lys (L 18), romurtide.
Shimoda K; Okamura S; Harada N; Omori F; Niho Y
Res Commun Chem Pathol Pharmacol; 1990 Dec; 70(3):289-96. PubMed ID: 2093210
[TBL] [Abstract][Full Text] [Related]
38. Muroctasin [MDP-Lys(18)] augments the production of granulocyte colony-stimulating factor (G-CSF) from human peripheral blood mononuclear cells in vitro.
Shimoda K; Okamura S; Kawasaki C; Omori F; Matsuguchi T; Niho Y
Int J Immunopharmacol; 1990; 12(7):729-36. PubMed ID: 1705535
[TBL] [Abstract][Full Text] [Related]
39. Hematological response to the new synthetic muramyl dipeptide derivative muroctasin after chemotherapy in patients with malignant lymphoma. A randomized crossover trial.
Hiraoka A; Masaoka T; Satoh T; Ota K; Oyama A; Horiuchi A; Hasegawa H; Nagai K; Kosaki M; Kanemaru A
Arzneimittelforschung; 1988 Oct; 38(10):1499-501. PubMed ID: 3058133
[TBL] [Abstract][Full Text] [Related]
40. Inflammatory cytokine production induced by an analogue of muramyl dipeptide MDP-Lys(L18) in rat macrophage cultures and dog synovial fluid.
Sugawara T; Takada S; Miyamoto M; Nomura M; Kato M
Inflammation; 1996 Feb; 20(1):43-56. PubMed ID: 8926048
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
